Dopamine D2-like receptor (D2-like DR) (D2-like DR)

The Dopamine D2-like receptor subfamily consists of the D2, D3, and D4 receptor subtypes, which are characterized by their coupling to Gi/o inhibitory G proteins (StatPearls, Physiology, Dopamine Receptors, 2023). These receptors function by inhibiting adenylyl cyclase activity, thereby reducing intracellular cyclic AMP (cAMP) levels and modulating various downstream signaling pathways (UniProt, Dopamine receptor D2, P14416). They are widely expressed in the brain, particularly in the striatum, nucleus accumbens, and pituitary gland, where they regulate motor function, reward-seeking behavior, and hormone secretion (PubMed, PMC4156299). In clinical practice, D2-like receptors are the primary targets for antipsychotic medications, which typically act as antagonists to alleviate positive symptoms of schizophrenia (NIH, Antipsychotic Medications, 2024). Conversely, dopamine agonists that stimulate these receptors are used to treat Parkinson's disease and restless legs syndrome by mimicking the effects of endogenous dopamine (PubMed, PMID: 16431221). However, modulation of these receptors is associated with significant side effects, including movement disorders and endocrine imbalances, due to their broad physiological roles (StatPearls, Antipsychotic Medications, 2023).

Other names

D2-type dopamine receptorD2-like receptor subfamilyD2RD3RD4R

Drugs targeting D2-like receptors act as antagonists to block overactive dopamine signaling in schizophrenia, partial agonists to modulate dopamine levels in mood disorders, or agonists to compensate for dopamine loss in Parkinson's disease.